Related Experiment Videos
[Toxicity of hydroxyapatite nanoparticles on rabbits]
Li-Ping Liu1, Yan-Bing Xiao, Zi-Wen Xiao
1Biomedical Engineering Dept, and Institute of Ultrasound Engineering in Medicine, Chongqing University of Medical Sciences, Chongqing 400016, China.
Wei Sheng Yan Jiu = Journal of Hygiene Research
|October 19, 2005
Summary
Nano-hydroxyapatite (nano-HA) shows no cumulative toxicity in rabbits when administered intravenously. Small dosages, significantly below the medium lethal dose, are suggested as safe for drug delivery applications.
Area of Science:
- Biomaterials Science
- Toxicology
- Nanotechnology
Context:
- Nano-hydroxyapatite (nano-HA) is being explored for drug delivery applications.
- Intravenous administration requires thorough toxicity assessment.
- Understanding nano-HA's biological interactions is crucial for safe clinical use.
Purpose:
- To evaluate the intravenous toxicity of nano-hydroxyapatite in a rabbit model.
- To determine the effects of varying nano-HA concentrations on physiological parameters.
- To establish safety profiles for potential therapeutic applications.
Summary:
- The medium lethal dose (LD50) for intravenous nano-HA in rabbits was determined to be 200 mg/kg.
- Transient increases in liver enzymes (LDH, CPK, GOP, GDT) and kidney function markers (BUN, ALP) were observed post-injection, returning to normal within 24 hours.
- Phosphorus levels increased, while calcium and magnesium remained stable, indicating no significant mineral imbalance.
Impact:
- Nano-hydroxyapatite demonstrates a favorable safety profile for intravenous use at sub-lethal doses.
- These findings support the potential of nano-HA as a safe drug carrier, even in anticancer therapies.
- The study provides critical toxicological data for the development of nano-HA-based therapeutics.